April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Evaluating safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens
Jan 24, 2025, 15:26

Evaluating safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens

Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, shared a post on X:

“Here’s a trial in leukemia MRD: AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

A peptide vaccine approach has been under investigation (2023) against a cancer driver (mutant RAS) in pancreatic cancer during minimal residual disease. AI needs to prove what it adds as the drivers of cancer are well known by experts. Why $500B?”

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients

Authors: Susanne Jung, Annika Nelde, Yacine Maringer, Monika Denk, Lisa Zieschang, Christine Kammer, Melek Özbek, Peter Martus, Christopher Hackenbruch, Alexander Englisch, Jonas S Heitmann, Helmut R Salih, Juliane S Walz.

Evaluating safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens